Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. Zajicek J, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ J Neurol Neurosurg Psychiatry. 2005 Dec; 76(12):1664-9. PMID: 16291891. Abstract CommentRecommendBookmarkWatch